Session translationnelle : Oncologie
mardi 24 juin 2025
Sessions parallèles
Sessions parallèles
•
S23
•
16h45
>
18h15
•
Session translationnelle : Oncologie
•
IFPS - Amphi 3
Sessions parallèles
Modérateurs : Adrien PROCUREUR (Paris), Audrey BELLESOEUR (Paris)
Conférence invitée
16h45 Anticorps drogue conjugués et anticorps bispécifiques, du mécanisme d'action à la pratique clinique - Angélique DA SILVA (Caen)
Communications orales
•
5
•
CO-031 - Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis
>
J.
Joachim
Alexandre
•
141
•
CO-032 - A population pharmacokinetics model for abatacept in patients with myocarditis induced by immune checkpoint inhibitor
>
D.
David
Combarel
•
192
•
CO-033 - Outcome of Bcr-Abl tyrosine kinase inhibitors rechallenge following pericardial effusion
>
B.
Blandine
Bertin
•
227
•
CO-034 - Immune Checkpoint Inhibitor-Associated Dermatomyositis: A Multicenter Cohort Study
>
P.
Pascale
Palassin
•
253
•
CO-035 - Development and evaluation of i-Tracker Pembrolizumab and i-Tracker anti-Pembrolizumab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with Pembrolizumab
>
J.
Julie
Poirier
•
298
•
CO-036 - Clinical efficacy of ramucirumab in advanced oeso-gastic and gastric junction cancer patients is influenced by its pharmacokinetics and target occupancy – a joint target-mediated drug disposition (TMDD) – time-to-event model
>
O.
Olivier
Le Tilly
|